Coalition for the Reversal of Breast Cancer Mortality in African American Women

A blog about research, awareness, prevention, treatment and survivorship of Breast Cancer and all cancers, including targeted scientific research and a grassroots approach to increase screening for cancer, especially in the low income and under-insured population of El Paso, Texas, with a view to expand this new health care model to many other 'minority' populations across the United States and beyond

Friday, January 25, 2013



 
ADAR 1
 Study: Enzyme Plays Important Role in CML Stem Cell Reprogramming
By Dave Levitan | January 18, 2013


Researchers have identified an enzyme that plays an important role in the reprogramming of malignant progenitor cells in chronic myeloid leukemia (CML). The enzyme, adenosine(Drug information on adenosine) deaminase acting on RNA 1 (ADAR1), could represent a target for selecting and eradicating leukemia stem cells, according to a paper published online ahead of print on December 28, 2012, in Proceedings of the National Academy of Sciences.
A small, hypolobated megakaryocyte in a bone marrow aspirate, typical of CML; source: Difu Wu, Wikimedia Commons
“Although the [chronic phase] of CML often can be controlled for long periods of time with standard TKI therapies, subsequent genetic and epigenetic alterations promote progenitor expansion and the generation of self-renewing leukemia stem cells that fuel disease progression and blast crisis transformation along with TKI resistance,” wrote study senior author Catriona H. M. Jamieson, MD, PhD, of the University of California, San Diego, and colleagues.

It is becoming more and more evident that RNA editing enzymes play a role in that promotion of self-renewing CML cells. In this study, researchers used whole-transcriptome sequencing of normal cells, as well as chronic phase and blast phase CML cells, to look for sources for reprogramming of progenitor cells.
They found that increased expression of the ADAR1 p150 isoform in blast crisis CML could be related to inflammatory pathway activation, including cytokines and tumor necrosis factors.
The investigators also examined whether limiting expression of ADAR1 could affect the self-renewal capacity of leukemia stem cells. They transplanted human CML cells with ADAR1 expression knocked down into mice and compared with control cells; they found an impaired ability to self-renew in the leukemia stem cells. “Although leukemic burden was not diminished significantly, the [leukemia stem cell] self-renewal capacity was irrevocably reduced by ADAR1 knockdown,” the authors wrote.
Together, these data suggest that inflammatory mediator-driven expression of ADAR1 contributes to CML progression.
In a press release, Dr. Jamieson noted that this adds further weight to inflammation as “an essential driver of cancer relapse and therapeutic resistance.” In particular, the importance of ADAR1 in CML represents a clear target for therapeutic strategies.
“ADAR1 is an enzyme that we may be able to specifically target with a small molecule inhibitor, an approach we have already used effectively with other inhibitors,” Dr. Jamieson said. “If we can block the capacity of leukemia stem cells to use ADAR1, if we can knock down that pathway, maybe we can put stem cells back on the right track and stop malignant cloning.”
  •  EMAIL  |  
  •  PRINT  |  
  •  PDF  |  
  •  REPRINT  |  
  •  SHARE
 

Join the Conversation

Want to join the conversation? If you're a healthcare professional, we'd like to hear your comments. Just sign in or register today to become part of our growing, online community.







CancerNetwork on Facebook


Posted by Peggy Kankonde at 3:22 AM
Email ThisBlogThis!Share to XShare to FacebookShare to Pinterest

No comments:

Post a Comment

Newer Post Older Post Home
Subscribe to: Post Comments (Atom)

Search This Blog

Breast Cancer Risk Factor Questionnaire

Click here to take survey

Steering Committee

Peggy Kankonde
View my complete profile

Popular Posts

  • Expression of MTOR can be quantified by the following:
    Expression of MTOR can be quantified by following PIK Raptor mLst8  Deptor TORC2 SGK Sin1 PRR5L By Western Blot, Flowcytometry
  • A novel virus genome discovered in an extreme environment suggests recombination between unrelated groups of RNA and DNA viruses
    A novel virus genome discovered in an extreme environment suggests recombination between unrelated groups of RNA and DNA viruses Geoffrey...
  • FLIPPASE, FLOPPASE, SCRAMBLASE
    One of nature's secret and ability to hide it, is by being simple.  While we expect things to be complicated and full of contorsions,  w...
  • Chromosome Translocation, an old scientific curiosity
    From Myelodysplasia to most cancers including T cell lymphoproliferative disorder, scientific readings continue to report how chromosomal tr...
  • Is the black hole evidence of the existence of parallel universe
    We all agree that black hole exist, they suck universal objects such as planets and suns and moon but for where....matters sucked will go w...
  • If all will end
    According to most astrophysicists, the world will end in an explosion caused by comet that will be large enough to cause cataclysmic shifts ...
  • (no title)
    Research has restarted This time with completion of our random selection of sera Indeed 64 patients,friends and neighbors have volunteered...
  • Death Center
    *There is nothing without substance for smoke to exist there must be fire at origin and since death is a phenomena, a death center must ex...
  • life, a continuum of structures
    Life secret is hidden in several dimensions distance among the suns and various planets, continuum of life structures, limitations of our m...
  • More and capable Telescopes
    when it comes to observing the Universe,  with our current means, comparison has been made that we can only look from our stand points.   B...

LINKS

  • Prevent Cancer
  • National 30 Year Cancer Prevention Study
  • Komen El Paso
  • City Beat El Paso Texas
  • Rio Grande Cancer Foundation
  • Breast and Cervical Cancer Prevention and Treatment Act of 2000
  • The Unmet Needs of African American Women with Breast Cancer
  • A NATION’S HEALTH AT RISK II: A FRONT ROW SEAT IN A CHANGING HEALTH CARE SYSTEM
  • Access Endangered: Profiles of the Medically Disenfranchised
  • Health Centers’ Role in Reducing Racial and Ethnic Health Disparities
  • Breast Cancer Facts and Figures 2011-2012
  • Community Health Centers: The Local Prescription for Better Quality and Lower Costs
  • Health Wanted - The State of Unmet Need for Primary Health Care in America
  • AACR Cancer Progress Report 2011

Blog Archive

  • ►  2019 (1)
    • ►  February (1)
  • ►  2017 (2)
    • ►  January (2)
  • ►  2016 (31)
    • ►  November (4)
    • ►  May (1)
    • ►  April (10)
    • ►  March (9)
    • ►  February (4)
    • ►  January (3)
  • ►  2015 (6)
    • ►  March (1)
    • ►  February (1)
    • ►  January (4)
  • ►  2014 (284)
    • ►  December (6)
    • ►  November (15)
    • ►  October (14)
    • ►  September (19)
    • ►  August (22)
    • ►  July (23)
    • ►  June (24)
    • ►  May (27)
    • ►  April (32)
    • ►  March (23)
    • ►  February (43)
    • ►  January (36)
  • ▼  2013 (913)
    • ►  December (47)
    • ►  November (47)
    • ►  October (45)
    • ►  September (53)
    • ►  August (59)
    • ►  July (59)
    • ►  June (85)
    • ►  May (100)
    • ►  April (90)
    • ►  March (94)
    • ►  February (107)
    • ▼  January (127)
      • Dear Komen friends, We are less than three weeks ...
      • ACTIVITY AT CRBCM WE HAVE NOW APPLIED FOR PROJECT...
      • TEMPLATE FOR HEPATOCELLULAR CARCINOMA FOLLOW-UP:
      • NOMENCLATURE OF GENES IN SARCOMA  (TO BE FURTHER D...
      • CELLULAR LANGUAGE The challenge brought to us by ...
      • State audit calls for extensive reforms of Texas...
      • OPINION ON GENETIC TESTING As our knowledge keep ...
      • UTERINE OR ENDOMETRIAL CANCER WITH INCREASE OF OB...
      • COMPLICATIONS ENCOUNTERED AT DEFINING GENE AMPLIFI...
      • Travis County DA: “The CPRIT investigation ...
      • CPRIT AUDIT REPORT IS ON THE LEVEL. ==============...
      • CPRIT HAS BEEN AUDITED
      • ASCO GI: Phase III Bevacizumab Results of the AVEX...
      • DIET FAILURES
      • OVEREXPRESSION OF SQLE GENE ON CHROMOSOME 8,  MARK...
      • NOMENCLATURE OF THE GENES OF PROLIFERATION, STILL ...
      • Can Metastasis of Triple-Negative Breast Can...
      • UPDATE ON TREATMENTS OF PERIPHERAL T CELL LYMPHOMA...
      • sCD163 and sTARC are disease response biomarkers...
      • GENETIC MUTATIONS GIVING FURTHER INSIGHT INTO HEMA...
      • Adrenaline Funk by Clement Albert on Ube...
      • PRELIMINARY DISCUSSION ON THE 4TH LAW. THE 4TH LA...
      • Medscape Medical News New Norovirus Strain Hits...
      • Op Ed from Vice Chair Barbara Canales 3:1...
      • FDA Approves Imatinib for Pediatric ALL Nick Mu...
      • FREE CPRIT MOVEMENT HAS BEEN CREATED! PEOPLE AND I...
      • NICE QUOTES FROM THE LANCET! VOLTAIRE :  "The art...
      • IN DEPTH INVESTIGATION, BRAIN INJURY--CRBCM (THIS ...
      • QUIZARTINIB ALLOWS TO BUY TIME BEFORE TRANSPLANT I...
      • SHORT NEWS FROM ASCO POST *For years we have been...
      •   ...
      • EVENTS GOVERNING CELLULAR LIFE Overall, life at t...
      • EXPERIMENT SUPPORTING THE 4TH LAW. TAKE YOUR SHOE...
      • COROLLARY POTENTIAL RESULTING FROM THE 3RD LAW As ...
      • Medscape Medical News AMD–Aspirin Link: Latest ...
      • Hello Clement Albert, (or Dr Kankonde)  see also...
      • WATCH OUT FOR HYPERTRIGLYCERDEMIA AND PANCREATITIS...
      • NOMENCLATURE OF GENES INVOLVED IN CELL PROLIFERATI...
      • FERTILITY PRESERVATION IN YOUNG ONCOLOGY PATIENTS....
      • The issue of clinical research and participation i...
      • ARSENIC TRIOXIDE COULD SIGNIFICANTLY EXPAND ITS RO...
      • NOMENCLATURE OF GENES DISCUSSED IN THE 3RD LAW (CO...
      • CONTINUE EDUCATION WITH NMCR ...
      • January 22, 2013 ...
      • FACTORS BEING MONITORED IN THE WELLNESS PROGRAM (p...
      • CPRIT Foundation and the CPRIT Grant review and ap...
      • WELLNESS PROGRAM (PART 1).  As we set out to pre...
      • Mutiple Myeloma management notes from training! --...
      • NOMENCLATURE OF GENES INVOLVED IN THE 3RD LAW. 1....
      • Monitoring Circulating Tumor Cells with the Cell...
      • IN METASTATIC DISEASE THAT IS ADVANCED, ONE OF THE...
      • CPRIT BACK IN THE NEWS! IN AN INTERVIEW JUST FEW ...
      • FOLLOWING UP ON THE 3RD LAW. (SWING OF THE PENDULUM)
      • THIRD LAW OF NATURE, NO PROLIFERATION AND CONCURRE...
      • An usere Leser aus Deutschland
      • TALKING DE-ACETYLATION, PANOBINOSTAT
      • JAK SIGNALING, STIMULATED BY INTERFERON AND OTHER ...
      • NEW LIPOSOMAL VINCRISTINE WITH EFFICACY IN RELAPSE...
      • PUTTING THINGS TOGETHER IN TRIPLE NEGATIVE BREAST ...
      • CancerNetwor...
      • The future is on the move!
      • Medscape Hematology-Oncology > Kris on Oncology ...
      • POLYUBIQUITINATION The rise of the role of antipr...
      • New Meta-Analysis on Sugar Sparks Old Debate ...
      • FDA Approval for Ixabepilone Brand name: Ixemp...
      • BRCA 1,2   BR=Breast   CA=cancer Tumor suppressor...
      •      ...
      • CPRIT Foundation releases donor list E...
      • CPRIT Foundation: Names are coming out of the hidi...
      • MICROSATELLITE INSTABILITY IN TRIPLE NEGATIVE BREA...
      • WHAT IS A DRIVER MUTATION ANYWAY? In a cell, ther...
      • NF-kB PATHWAY AND CANCER SURVIVAL, (Inhibitor: Par...
      • Lack of Clear Evidence for Sentinel Node Biopsy i...
      • Effective Treatment of Psoriasis with Narrow-Ban...
      • ASPECTS OF TARGET THERAPY IN TRIPLE NEGATIVE BREAS...
      • Breast cancer’s many drivers ...
      • A network module-based method for identifying can...
      • Fighting cancer with cell phones: Innovation to sa...
      • SCATTERED NEWS 1. Adding Velcade may increase rem...
      • ETIRINOTECAN PEGOL WAS GRANTED FAST TRACK BY THE F...
      • IS T-DM1 THE NEXT BIG THING IN HER-2 POSITIVE BREA...
      • Novel Cancer Hypothesis Suggests Antioxidants Are...
      • Salivary Gland Biopsy May Diagnose Parkinson's Di...
      • INTERFERON AND AFINITOR, A POTENTIAL COMBINATION F...
      • FDA APPROVES MANY DRUGS 1.CABOZANTINIB, A AMULTIK...
      • "NEVER MIND DRUG RESISTANCE" IN CLINICAL ONCOLOGY....
      • TRAVEL: Come spend 36 Hours in El Paso, Texas!
      • INFLUENZA? HOW MUCH? READ THIS ALERT FROM A HOSP...
      • Cancer Prevention and Research Institute of Texas ...
      • TRIPLE NEGATIVE BREAST CANCER, A MELTING POT The ...
      • Researchers from the Memorial Sloan K. have confir...
      • TAXOTERE-CISPLATIN SUPERIOR TO TAXOTERE-XELODA IN ...
      • Study: 1.3 Million Overdiagnosed Breast Cancers in...
      • Invitation to celebrate Dr. MLK Jr.
      • In a recent Article published in the December 15th...
      • FOR THE CURE, TIME FOR PARADIGM SHIFT AND A REVOLU...
      • MY FIRST NOVEL IS ATTRACTING MOVIE MAKERS: " A WHI...
      • This FOA (RFA-CA-12-015), using the R01 funding m...
      • IN A COMMUNICATION TO CPRIT'S EXECUTIVE DIRECTOR, ...
      • "RESEARCH MISCONDUCT ON THE RISE" This is the tit...
  • ►  2012 (188)
    • ►  December (109)
    • ►  November (45)
    • ►  October (29)
    • ►  August (3)
    • ►  July (1)
    • ►  May (1)

Contact::

Coalition for the Reversal of Breast Cancer Mortality in African American Women, 12640 Tierra Inca Dr, El Paso TX 79938.
Call: 765-969-2188
Coalition for the Reversal of Breast Cancer Mortality in African American Women . Copyright 2012. Ethereal theme. Theme images by enot-poloskun. Powered by Blogger.